% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • mid_swe mid_swe Jul 20, 2011 5:11 PM Flag

    New analysis from Zacks, 2.5$ 1 yr target.

    What will EPCT finance now as there is an upgrade?

    We always see an upgrade and BUY rec´s prior a PO/PP!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • After reading a Swedish board I have understood that you are campaigning on Epicepts board to punish some people that are bashing Oxigene, a CO that you are following close.

      If you have that goal, can you find a more precise way of communicating with those people you dislike?

      Zacks do have un update on the financial situation in Epicept:

      "As of March 31, 2011 EpiCept had $10.2 million in cash and cash equivalents. With the new financing,
      the Company should have cash of about $14 million as of June 30, 2011. Current cash is sufficient to
      fund operations into 2012. The Company also may receive cash from certain licensing activities during

      Epicepts burnate is some 1.2-1.3 MUSD/month.

0.43+0.030(+7.42%)Apr 28 3:59 PMEDT